Scientific presentation selector

Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, plus atirmociclib (ATI) in ER+/HER2− advanced or metastatic breast cancer (ABC): TACTIVE-K phase 1b/2 results

Telli ML, Ruiz-Borrego M, Yonemori K, Zhao Y, Jhaveri KL, Wang S, Patnaik A, Frenel JS, Xu P, Tran L, Lonning S, Berkowitz N, Zhang Y, Mazzoletti M, Fittipaldo A, Mukohara T

Neoadjuvant atirmociclib plus letrozole versus letrozole alone in HR+/HER2− breast cancer: Results from FourLight-2, a randomized phase 2 window of opportunity study

Goel S, Blancas López-Barajas MI, Allegrini G, Alonso Romero JL, Rodriguez-Lescure A, Lopez Tarruella S, Grela-Wojewoda A, Grinda T, Villanueva C, Sarti S, Kurzeder C, Cikman I, Beeram M, Lee KT, Basu C, Kim S, Liu F, Yao J, Ignatiadis M

Pharmacodynamic effects of the first-in-class CDK4‑selective inhibitor atirmociclib (PF‑07220060) in combination with endocrine therapy in tumors of patients with HR+/HER2− metastatic breast cancer

Giordano A, Liu F, Roh W, Zhang H, Flores Diaz DF, Hernandez CA, Wu X, Sanchez MC, Park J, Delioukina M, Moss RA, Yap TA

Randomized phase 3 clinical trial evaluating atirmociclib plus letrozole versus a CDK4/6 inhibitor plus letrozole as first-line treatment for patients with HR+/HER2− advanced/metastatic breast cancer

Bidard FC, Ignatiadis M, Curigliano G, Xu B, Link T, Naito Y, Li H, Iwase M, Taylor MA, Barrios CH, Osako T, Kalinsky K, Giordano A, Goel S, Santarpia L, Gong J, Fernandez KC, Zhang Z, Rugo HS

Long -term safety and efficacy of first-line next generation CDK4-selective inhibitor atirmociclib + letrozole for the treatment of patients with HR+/HER2− metastatic breast cancer

Yap T, Magallanes M, Xu B, Kaen DL, Korbenfeld EP, Yan M, Zayas-Villanueva OA, Hernández CA, Schmid P, Mego M, Bella SR, Wu X, Siddiqui M, Basu C, Park J, Gong J, Giordano A

Effect of atirmociclib plus endocrine therapy (ET) on serum thymidine kinase activity (TKa) in a phase 1 study of patients with HR+/HER2−metastatic breast cancer (mBC)

Schmid P, Sharma MR, Giordano A, Howell SJ, Magallanes M, Kaen DL, Liu F, Zhang H, Chang YW, Park J, Holynskyj A, Yap TA

The next-generation CDK4-selective inhibitor atirmociclib (PF-07220060) in combination with letrozole as first-line treatment in patients with HR+/HER2+ metastatic breast cancer

Giordano A, Magallanes M, Xu B, Kaen D, Korbenfeld E, Yan M, Villanueva OZ, Hernandez CA, Schmid P, Mego M, Bella S, Wu X, Liu F, Basu C, Park J, Neumann H, Delioukina M, Yap TA

Randomized phase 2 window of opportunity trial comparing the effect of preoperative atirmociclib (PF-07220060) plus letrozole versus letrozole alone on Ki-67 tumor expression in postmenopausal women with HR+/HER2– breast cancer

Goel S, Zaman K, Im SA, Elkhanany A, Huang CS, Villanueva C, Tarruella SL, Chung CH, Alcasid A, Liu Y, Basu C, Ignatiadis M

Concentration-QTc analysis of PF-07220060 in patients with advanced solid tumors

Gao X, Ousey J, Delioukina M, Zhou L, Williams JH, Hoffman JT, Yang J

Longitudinal circulating tumor DNA (ctDNA) dynamics in phase 1/2a study of the first-in-class CDK4-selective inhibitor, atirmociclib (PF-07220060), in combination with endocrine therapy in patients with HR+/HER2– metastatic breast cancer (mBC) who progre

Yap TA, Liu F, Zhang H, Roh W, Giordano A, Hamilton EP, Delioukina M, Lira M, Park J, Basu C, Sharma MR

PHASE 1B/2 FIRST-IN-CLASS NOVEL COMBINATION TRIAL OF NEXT GENERATION CDK4-SELECTIVE INHIBITOR PF-07220060 AND NEXT GENERATION CDK2-SELECTIVE INHIBITOR PF-07104091 IN HR+ HER2- METASTATIC BREAST CANCER AND ADVANCED SOLID TUMORS

Yap T, Yan F, Sadeghi S, Lin T, Liu F, Malky L, Golmakani M, Moreau A, Neumann H, Zhou L, Juric D, Sharma M